Trial Profile
A Phase I/II Study of the Safety, Tolerability, and Immunogenicity of a Topical Therapeutic DNA Dendritic Cell Vaccine (DermaVir Patch) in Children, Adolescents, and Young Adults With HIV-1 Infection on Highly Active Antiretroviral Therapy (HAART)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs LC 002 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- 08 Jul 2013 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 06 May 2013 Planned end date changed from 1 Nov 2012 to 1 Nov 2013 as reported by ClinicalTrials.gov.
- 26 Mar 2012 Planned end date changed from 1 Sep 2010 to 1 Nov 2012 as reported by ClinicalTrials.gov.